Biotech Sector Action Alert

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts


 

Why Are Investors Looking At The Biotech Sector?

Because… its BIG!

 

Big Pharma & Medical Device Market Headlines:

 

“Global Biotechnology Market is set to exceed USD 775 billion by 2024”

https://www.gminsights.com

 

“Medical Devices… a disruptive market of $410 billion until 2023…” (Forbes)  https://www.forbes.com/sites/yiannismouratidis/2018/12/09/the-rise-of-use-of-medical-devices-force-fda-to-change-the-rules/#383d00b32101

 

What Products & Services Make Up This Industry in the US?

 

The Biotechnology in the US industry consists of Human health technologies (including drugs/medicines & medical devices), animal health, marine and terrestrial microbial technologies, environmental remediation and natural resource recovery, agriculture and aquaculture technologies and industrial technologies.

 

How is the Industry Trending in the US?

 

Over the past five years, the Biotechnology in the US industry has grown by 1.5% to reach revenue of $108bn in 2018. In the same timeframe, the number of businesses has grown by 1.1% and the number of employees has grown by 0.2%.

 

Biotechnology Market size is set to exceed USD 775 billion by 2024; according to a new research report by Global Market Insights. Growing incidence of chronic diseases will boost biotechnology market growth over the forecast timeline.

 

Innovations in biotechnology sector is expected to upsurge revenue size during the forecast period. Innovations… with rising demand for novel biotechnological products will favor business growth. Wide-ranging applications coupled with growing demand for effective drugs and vaccines should favor business growth. Improving healthcare access in areas of unmet medical needs and growing R&D expenses for biotechnology advances will spur revenue size. Moreover, rising demand for agriculture based products and growing demand for biotechnology practices in clinical research will endure to foster biotechnology industry growth. https://www.gminsights.com/industry-analysis/biotechnology-market

 

What does the U.S. Medical Device picture look like?

 

U.S. remains the largest medical device market in the world, with a market size of around $156 billion as well as representing about 40 percent of the global medical device market last year alone

 

Compared to several other industries including automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation, reflecting the competitive nature of the industry and constant innovation and improvement of existing technologies.

 

The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development. Collaborations have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector’s ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future.

https://www.selectusa.gov/medical-technology-industry-united-states

 

What do the markets look like?

 

Forbes said the following: “It’s been well appreciated by market analysts that the universe of U.S. public equities has shrunk remarkably over the past 20 years, from nearly 8000 listed companies in 1996 to just over 4000 today.  A combination of fewer gains (new listings like IPOs) and more listing losses (from M&A and delistings) has dramatically reduced the pool of public stocks investors can trade by almost 50% over two decades.

 

Today we are five years into a sustained, open, and accommodative IPO market, the most prolific for new offerings in biotech history.  Since 2011, we’ve seen over a 50% increase in the number of publicly-traded biotech companies… demand for biotech IPOs and the opportunity to back new potential therapies has grown considerably vs in the past two decades.  Biotech, and healthcare at large, have represented nearly two of every five IPOs, according to Renaissance Capital, over the past few years – 3-4x greater than biotech’s share of the private company universe.

About FinancialNewsMedia.com

Linking the Financial World through Technology & Innovation.

 

FinancialNewsMedia.com has many years of experience assisting public companies, large and small, navigate a wide range of Financial Public Relations needs for Micro Cap to Small Cap to Large Cap Companies. Our approach includes strategic orientated goals for our clients that can save time and money while delivering the right outcomes. Our News Media campaigns are strategically executed to generate maximum exposure and stimulate retail investor awareness.

 

FinancialNewsMedia.com provides top tier media solutions to disseminate, amplify and target a company’s news and corporate developments utilizing innovative news media services, social media and multimedia platforms. We effectively distribute vitally important news & content with measured results across traditional, digital and social channels. Combining the most cost effective multimedia-channels and content distribution communications technology with powerful workflow tools and cutting edge online media platforms, FinancialNewsMedia.com enables public companies and IR professionals to engage opportunity everywhere it exists.

 

FinancialNewsMedia.com provides established and emerging public companies a suite of comprehensive products & solutions along with one of the kind strategic consulting services built on years of Financial Marketing, Information Technology and Communications experience. FNM understands the importance to successfully establishing corporate visibility throughout the high paced investment community and financial marketplace and we are committed to providing the markets highest quality, one source destination for publicly traded corporations and IR professionals. For more information, visit the FNM Product & Services or email us at solutions@FinancialNewsMedia.com.

 

FinancialNewsMedia.com (FNM) is a leading provider of proactive news distribution services and engaging financial public relations. FNM specializes in Powerful Dissemination Solutions, Targeted Media Communications, Financial Outreach & Awareness Campaigns, Amplified News Services and so much more. We are continually leveraging the latest communications technology and influential media platforms providing a comprehensive suite of powerful tools for today’s emerging public companies to successfully reach the retail investor community. Now more than ever, a company’s vitally important news and corporate message is effectively amplified to a larger audience utilizing unparalleled multimedia channels aimed at increasing exposure and maximizing corporate online visibility in today’s highly competitive financial marketplace.

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!